Bioxytran Reports 90% Day-5 Viral Clearance for ProLectin-M in Phase 1b/2a COVID-19 Study

summarizeSummary

Bioxytran announced positive Phase 1b/2a clinical trial results for its antiviral drug ProLectin-M in mild to moderate COVID-19, demonstrating statistically significant earlier viral clearance and a favorable safety profile.

check_boxKey Events

• Positive Phase 1b/2a Clinical Results

  Bioxytran reported positive results from a randomized, double-blind, placebo-controlled Phase 1b/2a study of oral ProLectin-M in hospitalized patients with mild to moderate COVID-19.

• Statistically Significant Viral Clearance

  The highest dose of ProLectin-M (16,800 mg/day) achieved 90% non-detectable viral shedding by Day 5, significantly higher than the 20% observed in the placebo group (p=0.001).

• Favorable Safety Profile

  ProLectin-M was well tolerated at all evaluated dose levels, with no serious adverse events or treatment-related discontinuations.

• Differentiated Antiviral Mechanism

  ProLectin-M is designed to target galectins, blocking viral entry mechanisms, representing a novel antiviral strategy with potential applicability across multiple viral infections.

auto_awesomeAnalysis

This filing provides strong positive clinical data for Bioxytran's lead drug candidate, ProLectin-M, specifically in the context of COVID-19. The statistically significant 90% viral clearance by Day 5 at the highest dose, compared to placebo, is a critical indicator of efficacy. For a clinical-stage biotechnology company with a small market capitalization, such positive trial results are highly impactful, validating its carbohydrate-based therapeutic approach and supporting further development. This news builds on previous positive results for ProLectin-M and could significantly enhance investor confidence and the drug's commercial prospects.